Clinical Trial Update: A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing first-line JS001 + nab-paclitaxel vs palbociclib + nab-paclitaxel in advanced recurrent/metastatic triple negative breast cancer is susp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• JS001 (PD-1 inhibitor)
• Nab-paclitaxel (paclitaxel protein-bound)
• Palbociclib (palbociclib)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Triple Negative Breast Cancer | Phase 3 | Status: SUSPENDED